News In Brief
This article was originally published in The Silver Sheet
Executive Summary
Office of Management and Budget signals that it will finish reviewing eMDR rule by December; FDA searches for electronic portal for IMDRF single-audit initiative; and more.
You may also be interested in...
FDA’s ISO Audit Program Chugs Along; May Be Absorbed By IMDRF Single-Audit Initiative
Thirty manufacturers have used FDA’s ISO 13485 voluntary audit program since the two-year pilot began last June, freeing up scarce agency inspectional resources to be used elsewhere. However, it will likely be eventually absorbed by a pilot Medical Device Single Audit Program currently under development by the International Medical Device Regulators Forum.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.